BridgeBio Soars After FDA OKs Rival To Pfizer's Heart Drug
BridgeBio received early approval to launch its drug, acoramidis, for treating transthyretin amyloid cardiomyopathy. The drug, to be sold as Attruby, will compete with Pfizer's Vyndaqel.